Summary
Tesamorelin is a synthetic research peptide modeled on growth hormone–releasing hormone (GHRH). It features an N-terminal trans-3-hexenoic acid modification that confers resistance to enzymatic degradation by dipeptidyl peptidase-4, extending its functional half-life relative to native GHRH.
Overview
Tesamorelin is a synthetic, modified GHRH analog used as a reference compound in literature on the somatotropic axis. The N-terminal modification was engineered specifically to slow proteolytic cleavage at the conserved DPP-4 cleavage site, while preserving binding at the GHRH receptor.
Research Background
Tesamorelin was developed by Theratechnologies (formerly Theratope) and described in the GHRH-analog literature in the mid-2000s. It belongs to a family of structurally stabilized GHRH analogs that also includes LTF-SERM (the unmodified GHRH(1-29) fragment) and CJC-1295 (a different modification strategy).
Mechanisms Studied
Mechanistic interest centers on agonist activity at the GHRH receptor, the structural basis for its extended half-life relative to native GHRH, and the downstream cAMP-mediated signaling cascade that follows receptor engagement. Comparative-pharmacology work has examined how the structural modification affects receptor affinity and intrinsic activity.
Published Research Summary
Ferdinandi et al. (2007) describe the pharmacology and pharmacokinetics of tesamorelin (TH9507) in preclinical and early human-research settings, establishing the extended half-life relative to native GHRH. Reviews of GHRH-analog pharmacology (Stanley 2011, Falutz 2011) position tesamorelin within the broader analog family.
Quality & Verification
For research compounds, lot-level documentation is the starting point for any analytical work. Researchers commonly examine batch-specific Certificates of Analysis, reversed-phase HPLC purity readouts, mass-spectrometry confirmation of molecular weight, and lot identification to evaluate compound identity, purity, and consistency before downstream experiments.
References & Published Research
- Ferdinandi ES et al. — Non-clinical pharmacology and safety evaluation of TH9507 (tesamorelin), a synthetic analogue of human GHRH
- Stanley TL, Grinspoon SK — Effects of growth hormone-releasing hormone on visceral fat and metabolic parameters
- Falutz J — Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy